© 2020 MJH Life Sciences and Practical Cardiology. All rights reserved.
© 2020 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
September 28, 2020
Kazem Rahimi, MD, discusses the prospect of home monitoring for heart failure patients and how technology needs to improve before it is a viable option for most patients.
September 07, 2020
Dr. Gregory Weiss compiles thoughts and perspective on hot line trials presented at ESC Congress 2020.
September 06, 2020
Lead investigator of the PARALLAX trial discusses whether he feels clinical data related to sacubitril/valsartan is strong enough to warrant prescribing it for HFpEF patients.
September 03, 2020
Milton Packer, MD, discusses how EMPEROR-Reduced data influences the way clinicians view the SGLT2 inhibitor class and its uses.
August 30, 2020
Full results of the DAPA-CKD trial from ESC Congress 2020 detail the effects of dapagliflozin (Farxiga) among chronic kidney disease patients with and without type 2 diabetes.
Results of the PARALLAX trial shed light on the effects of sacubitril/valsartan (Entresto) in patients with heart failure with preserved ejection fraction.
August 29, 2020
Results of the phase 3 EMPEROR-Reduced trial indicate the SGLT2 inhibitor empagliflozin was effective for patients with HFrEF regardless of whether the patients had diabetes or not.
August 15, 2020
An analysis of more than 20 studies and 70k patients details the impact cardiovascular risk factors and complications can have on outcomes in patients hospitalized with COVID-19.
August 14, 2020
New data suggests sex hormone levels could help predict development of heart failure in older men and postmenopausal women.
August 07, 2020
A new analysis of a Medicare-linked database is detailing associations between loop diuretic use and nonuse after heart failure hospitalization with 30-day clinical outcomes.